Senior Notes Pricing, Contract Renewal, Updated Financial Outlook, Price Movements, and Clinical Trial Results - Research Report

   Senior Notes Pricing, Contract Renewal, Updated Financial Outlook, Price
    Movements, and Clinical Trial Results - Research Report on Endo, HCA,
                    Covidien, Vertex, and Seattle Genetics

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 19, 2013

NEW YORK, December 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Endo
Health Solutions Inc. (NASDAQ: ENDP), HCA Holdings, Inc. (NYSE: HCA), Covidien
plc (NYSE: COV), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), and
Seattle Genetics Inc. (NASDAQ: SGEN). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Endo Health Solutions Inc. Research Report

On December 11, 2013, Endo Health Solutions Inc. (Endo) announced that its
wholly-owned subsidiary, Endo Finance Co., has priced $700 million aggregate
principal amount of 5.75% senior unsecured notes due January 2022 at an issue
price of $1,000 per $1,000 principal amount in connection with its previously
announced private offering. Endo intends to use the net proceeds from the
offering, together with borrowings under the term loan portion of a new senior
secured credit facility, to refinance its existing senior secured credit
facility, to pay related fees and expenses and for general corporate purposes,
which may include strategic acquisitions. The Full Research Report on Endo
Health Solutions Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/059c_ENDP

--

HCA Holdings, Inc. Research Report

On December 13, 2013, HCA Holdings, Inc. (HCA) and Florida Blue announced a
contract renewal that ensures Florida Blue members will continue to have
access to high quality care at HCA's 42 hospitals and 32 surgery centers
throughout Florida. "HCA and Florida Blue share a commitment to providing high
quality, high value care to Floridians," said Juan Vallarino, Senior Vice
President of Employer and Payor Engagement, who leads managed care
negotiations for HCA. "We're pleased to renew this agreement and continue to
provide Florida Blue members access to the premier care HCA provides." The
Full Research Report on HCA Holdings, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/be59_HCA

--

Covidien plc Research Report

On December 16, 2013, Covidien plc (Covidien) announced supplemental
information and additional changes in connection with its revenue reporting
format. According to the Company, the new format provides a worldwide view of
sales across three major product categories while enhancing geographic
reporting by breaking out non-U.S. sales into new categories for emerging and
non-U.S. developed markets. The Company informed that it will begin using this
format when it releases its Q1 FY 2014 results in January 2014. "Our new
revenue reporting format more closely reflects the way we operate our
business, providing our stakeholders with enhanced transparency," said Charles
J. Dockendorff, Executive Vice President & Chief Financial Officer, Covidien.
"This approach underscores our continuing commitment to communicating our
business results clearly and consistently." Further, the Company reported that
it continues to estimate net sales in FY 2014 will be up 2% to 5% YoY, while
sales are expected to be up 3% to 6% YoY for Surgical Solutions; up 3% to 6%
YoY for Vascular Therapies; and up 1% to 4% YoY for Respiratory & Patient
Care. The Full Research Report on Covidien plc - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/a14c_COV

--

Vertex Pharmaceuticals Incorporated Research Report

On December 16, 2013, Vertex Pharmaceuticals Inc. (Vertex) stock declined
0.64% to end the day with $64.76. The Company's stock went down by 0.57% over
the past three trading days, compared to the Dow Jones Industrial Average
which went up by 0.26% during the same trading period. The Full Research
Report on Vertex Pharmaceuticals Incorporated - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/e696_VRTX

--

Seattle Genetics Inc. Research Report

On December 10, 2013, Seattle Genetics, Inc. (Seattle Genetics) announced
updated results from a phase 2 clinical trial of ADCETRIS (brentuximab
vedotin) in diffuse large B-cell lymphoma (DLBCL) and other B-cell non-Hodgkin
lymphomas. "In DLBCL, patients with relapsed or refractory disease have poor
outcomes, and there is a significant need for better therapeutic approaches to
treat this aggressive non-Hodgkin lymphoma subtype," said Jonathan Drachman,
M.D., Chief Medical Officer and Executive Vice President, Research and
Development at Seattle Genetics. "We are encouraged by the interim phase 2
results which demonstrated that single-agent ADCETRIS induced a 42 percent
objective response rate and manageable safety profile among advanced DLBCL
patients, including a high percentage whose disease was refractory to their
prior therapy. Based on these data, we have expanded our clinical program for
ADCETRIS in DLBCL both as a single-agent and in combination with standard
regimens for both relapsed and newly diagnosed patients." The Full Research
Report on Seattle Genetics Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/ff98_SGEN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.